Race for Corona vaccine: 25 vaccine candidates in clinical trials

Race for Corona vaccine: 25 vaccine candidates in clinical trials
Race for Corona vaccine: 25 vaccine candidates in clinical trials
Share post:

mobile phones 

With the number of infections on the rise again in some regions, researchers around the world are frantically working on potential vaccines against the coronavirus and drugs for the treatment of COVID-19, the lung disease caused by the virus. The pharmaceutical companies and universities racing to develop a corona vaccine are making strides: according to the World Health Organisation (WHO), 25 candidates are currently undergoing clinical trials.

Before an active substance is approved as a drug on the market, it must undergo several test phases. The first of these are the so-called preclinical studies. Once the vaccine has been developed in the laboratory, it is first tested in vitro – in a test tube, as it were – on organic molecular compounds and cell cultures. This is followed by tests on living, non-human organisms – from simple bacteria to laboratory animals. According to the WHO, 141 vaccine candidates are currently in this preclinical test phase.

Promising candidates for a drug will then be approved for clinical trials. During the so-called “phase 1”, an active substance is first tested on healthy, voluntary test candidates. Initially, only general tolerability and safety of administering the drug is to be demonstrated. If this phase is successful, the active ingredient moves on to phase 2 and phase 3. The goal of phase 2 is to demonstrate the general efficacy of the potential drug a small group of actual patients. Finally, in phase 3, a larger group of patients will be treated with the drug, among other things to address questions such as dosage and side effects. Only after successful completion of phase 3 can marketing authorization for a drug be applied for.

Five vaccine candidates currently in final testing phase before approval

According to the WHO, five vaccine candidates have already moved on to phase 3 and are thus in the final stage before potential market approval. Among them are three active ingredients developed by Chinese institutes. The Chinese pharmaceutical company Sinovac has recently started the third test phase of its vaccine candidate in Brazil.

An active ingredient co-developed by the University of Oxford and British pharmaceutical group AstraZeneca is also well along in development. According to a study published in the journal “The Lancet”, the vaccine proved to be well-tolerated in previous test series and stimulated the formation of antibodies to cause immunisation against COVID-19. The results of the decisive third test phase are expected in autumn. If successful, the pharmaceutical company plans to launch a coronavirus vaccine by the end of the year. According to AstraZeneca CEO Pascal Soriot, this vaccine will be sold worldwide “at cost price” of approximately EUR 2.50 per unit. The prospect of a corona vaccine has been well received on the stock exchange, and AstraZeneca’s share price has risen by around 13 per cent since the beginning of the year.

A vaccine from the US pharmaceutical company Moderna has already been approved for Phase 3. The company recently received a grant of USD 486m from the US government. As part of its “Warp Speed” programme to combat the virus, the US government has already granted huge sums of money to several vaccine projects.

 

According to the WHO, 13 active ingredients are currently at least partially in Phase 2 studies. Great hopes rest on a vaccine co-developed by US pharma company Pfizer and the German biopharmaceutical company BioNTech. Unlike AstraZeneca and China’s pharmaceutical companies, the two companies are working with a vaccine type that uses ribonucleic acid. This chemical messenger substance contains instructions for the production of proteins. The body recognises these virus-like proteins as intruders and can thus trigger an immune response against the actual virus.

A total of four RNA vaccine candidates from BioNTech and Pfizer are currently undergoing Phase 1 and 2 studies in the US and Germany. According to experts, initial results of these studies in the USA have been positive. 45 human test subjects developed antibodies against the SARS-CoV-2 pathogen. However, it is still unclear whether these antibodies actually protect against infection. Further tests with up to 30,000 test subjects are expected to reveal this information.

Pfizer and BioNTech now plan to start further phase 3 studies as soon as possible. For example, Brazil, which has been hit particularly hard by the pandemic, has recently approved the German-American vaccine candidate for testing after Sinovac and AstraZeneca. If the pending studies are successful, the application for approval is to be submitted in October. The US has already ordered more than 100 million doses of the active ingredient for close to USD 2bn.

Vaccine fantasy boosts share prices

With the hope of finding a vaccine candidate, BioNTech has recently also attracted attention on the stock exchange. The company has been listed on the US technology exchange Nasdaq since October 2019. Since the beginning of the year, the price of BioNTech’s depository receipts (ADR) has already risen by around 161 per cent. With a capital increase, the company has recently raised around USD 512m, thus securing further funds for vaccine development.

The German vaccine developer CureVac has now also started clinical trials. Its active substance is expected to be ready for the market by mid-2021. CureVac is also planning an IPO in the USA. The main investor in CureVac is currently Dievini, the SAP founder Dietmar Hopp’s investment company. In addition, both the German government and British pharmaceutical company GlaxoSmithKline have recently invested in CureVac to the tune of 23 per cent and 10 per cent respectively.

Austrian-French company Valneva, with a research site in Vienna, is also currently working on a vaccine candidate. The company formed through the merger of Austrian Intercell and French Vivalis plans to start clinical trials of its potential corona vaccine in November or December.  Against this background, the stock market price of Valneva has already nearly doubled this year.

In addition to the development of novel vaccines against the corona virus, the company is also testing the efficacy of existing drugs for treatment worldwide, with hopes resting on the drug Remsdesivir distributed by US pharmaceutical company Gilead, for one. The drug was originally developed for the treatment of the viral disease Ebola, but was never approved for this use.

Remdesivir is now regarded as one of the few effective drugs for treating severe cases of the lung disease caused by the virus. The European Medicines Agency (EMA) has recommended approval for patients aged 12 years and older. Doctors do not see Remdesivir as a panacea, but as a ray of hope for corona patients. The drug dexamethasone, produced by Nichi-Iko Pharmaceutical, has also been shown in studies to reduce mortality in patients and has now been approved for treatment in Japan.

Austrian company Marinomed set to test its active ingredient carragelose

The listed Austrian company Marinomed also wants to test its active ingredient carragelnose in a clinical study against the coronavirus. Cell tests have shown that carragelose has the potential to reduce the risk of contracting COVID-19, or possibly to treat the disease.

The biotech company already has products for the treatment of colds on the market, whereby the active substance is applied in the nose and throat. Come next year, a product for inhalation is to be launched that is effective against the virus in the lungs; “provided the clinical data allow for it,” said Marinomed CSO Eva Prieschl-Grassauer at a press conference.

With increased concentration of the active substance, more than 90 per cent of the virus could be suppressed. The product was developed for use against colds to protect the cells against penetration by viruses. A cell test has now shown that the active ingredient can also protect cells against the novel coronavirus.

ERSTE STOCK BIOTEC benefits from rising healthcare expenditure

Some of the companies mentioned are also included in the portfolio of ERSTE STOCK BIOTEC. Erste Asset Management’s equity fund, which was launched in April 2000, shows a positive performance of 2.8 per cent* this year (as of 24 July 2020, source Reuters Eikon), calculated over 5 years the performance is minus 0.62 per cent per year*, see chart. Since the fund was launched, a remarkable increase in value of 8.9 percent per year* has been achieved.

Fund manager Harald Kober, who closely monitors the development of corona vaccines, does not believe that only one cure or one vaccine will achieve the breakthrough. There will be several active ingredients from different companies that have different modes of action – for example for the elderly or other groups – Kober said in an interview with the daily newspaper Die Presse. It is questionable whether this is the way to earn big money, especially since many companies want to make their products available at cost price. In addition, there are still uncertainties, for example on the question of how long the vaccinated persons remain immune or how many doses are needed.

*The performance is calculated in accordance with the OeKB method. The management fee as well as any performance-related remuneration is already included. The issue premium of up to 4,00 % which might be applicable on purchase and as well as any individual transaction specific costs or ongoing costs that reduce earnings (e.g. account- and deposit fees) have not been taken into account in this presentation. Past performance is not a reliable indicator of the future performance of a fund.

 Will Corona be “big business”?

The biotechnology sector benefits from many other fields of activity, for example the fight against different types of cancer or diseases for which no effective treatment is yet available. The Covid crisis has shown how important expensive research and development is. In view of the ageing world population, it is also necessary to advance diagnostics in order to reduce the burden on public funds. The industry will grow independently of the economic situation, emphasised Kober.

Investors who are considering entering the biotechnology sector are well advised to do so with a broad diversification, such as that offered by ERSTE STOCK BIOTEC. This is because it has often been shown in the past that the share prices of promising companies rise rapidly, but can also fall all the more rapidly if high expectations are disappointed. Conversely, the biotechnology sector promises above-average growth opportunities in view of the ageing of society and the still large number of diseases that have not been defeated. A correspondingly long-term investment horizon is essential.

Legal note:
Prognoses are no reliable indicator for future performance.

DOSSIER

RESPOND TO THE ARTICLE

Leave a comment Required fields are marked with *

Your email address will not be published. Required fields are marked *

Legal disclaimer

This document is an advertisement. Unless indicated otherwise, source: Erste Asset Management GmbH. Our languages of communication are German and English.

The prospectus for UCITS (including any amendments) is published in Amtsblatt zur Wiener Zeitung in accordance with the provisions of the InvFG 2011 in the currently amended version. Information for Investors pursuant to § 21 AIFMG is prepared for the alternative investment funds (AIF) administered by Erste Asset Management GmbH pursuant to the provisions of the AIFMG in connection with the InvFG 2011. The fund prospectus, Information for Investors pursuant to § 21 AIFMG, and the key investor document/KID can be viewed in their latest versions at the web site www.erste-am.com or obtained in their latest versions free of charge from the domicile of the management company and the domicile of the custodian bank. The exact date of the most recent publication of the fund prospectus, the languages in which the key investor document is available, and any additional locations where the documents can be obtained can be viewed on the web site www.erste-am.com.

This document serves as additional information for our investors and is based on the knowledge of the staff responsible for preparing it at the time of preparation. Our analyses and conclusions are general in nature and do not take into account the individual needs of our investors in terms of earnings, taxation, and risk appetite. Past performance is not a reliable indicator of the future performance of a fund.